LubomirSokolMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Physician

Overview of Dr. Sokol

Dr. Lubomir Sokol is a hematologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. He received his medical degree from University Karlovy, Lek Fak Ii and has been in practice 36 years. Dr. Sokol accepts several types of health insurance, listed below. He is one of 46 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 6 doctors at Tampa General Hospital who specialize in Hematology. He has more than 100 publications and over 500 citings.

Office
12902 USF Magnolia Drive
Tampa, FL 33612
Book by Phone+1(229) 597-2431

Fax+1 813-745-5959

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2000 - 2002
LSU Health Sciences Center/University Hospital and Clinics (Lafayette)Residency, Internal Medicine, 1997 - 1999
University Karlovy, Lek Fak IiClass of 1981

Certifications & Licensure

FL State Medical License 2000 - 2026
LA State Medical License 1999 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013

Clinical Trials

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2008 Jul 09
Completed
Phase 2
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Start of enrollment: 2012 Mar 30
Active, not recruiting
Phase 2
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly Start of enrollment: 2013 Mar 01
Withdrawn
Not Applicable
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Start of enrollment: 2014 Apr 01
Terminated
Not Applicable
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2019 Nov 12
Terminated
Phase 2
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases Start of enrollment: 2021 Jul 14
Recruiting
Phase 2
Roles: Contact
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) Start of enrollment: 2023 Feb 15
Recruiting
Early Phase 1
Roles: Contact, Principal Investigator
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms Start of enrollment: 2023 Mar 29
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Francine M Foss, Youn H Kim, H Miles Prince, Oleg E Akilov, Christiane Querfeld
Journal of Clinical Oncology. 2024-12-19
Haematogenous seeding in mycosis fungoides and Sézary syndrome: Current evidence and clinical implications.
Robert Gniadecki, Emmanuella Guenova, Christiane Querfeld, Jan P Nicolay, Julia Scarisbrick
The British Journal of Dermatology. 2024-11-15
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.
Amrita Goyal, Daniel O'Leary, Bouthaina Dabaja, Wen-Kai Weng, Jasmine Zain
Transplantation and Cellular Therapy. 2024-11-01

Journal Articles

Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study
Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer

Abstracts/Posters

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience
Lubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Bnz-1, a Selective _-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: ...
Lubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Blockade of IL-15 Utilizing Bnz-1, a Selective _-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemi...
Lubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R
Lubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018

Press Mentions

Hospitalization Outcomes in Patients with CTCL: A Multi-Center StudyMarch 26th, 2022
Poster Awards Announced Ahead of 2022 Meeting in BostonMarch 7th, 2022
Potential New Drug Target to Treat Cutaneous T Cell LymphomaDecember 21st, 2020

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment